Healthy Skepticism Library item: 5531

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

MaLAM Letter follow up—Bayer aspirin and nimodipine
MaLAM International Newsletter 1993 Jan1-2

Abstract:

Since MaLAM wrote to Bayer about the marketing of aspirin for prevention of cataracts there has been an editorial in the Lancet on this subject. Bayer did not comment on the promotion of nimodipine in Indonesia and the company said it was unable to comment about promotion of this drug in Panama because it could not obtain a sample of the advertising.

Keywords:
*analysis/Indonesia/Panama/developing countries/aspirin/nimodipine/company responses/quality of information/Bayer/MaLAM/Medical Lobby for Appropriate Marketing/ETHICAL ISSUES IN PROMOTION: COMPANY STANDARDS/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPING COUNTRIES/REGULATION, CODES, GUIDELINES: FEEDBACK TO COMPANIES